← 返回

TIL(肿瘤浸润淋巴细胞)的进展:历史洞见、当代里程碑与肿瘤治疗的未来方向

英文原题:Advancements in tumor-infiltrating lymphocytes: Historical insights, contemporary milestones, and future directions in oncology therapy.

查看英文原题

Advancements in tumor-infiltrating lymphocytes: Historical insights, contemporary milestones, and future directions in oncology therapy.

PubMed 2024/08/08(内容时间) Crit Rev Oncol Hematol Q1 · IF 6.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

TIL(肿瘤浸润淋巴细胞)(TILs)是一种浸润并聚集在肿瘤内的免疫细胞亚型。研究证明,TILs可作为癌症患者对免疫治疗反应的预后和预测标志物。本综述探讨了关于TILs的现代知识、在癌症治疗中利用TILs所面临的挑战和机遇,例如TIL环境下疗法的兴起、TIL活性生物标志物的鉴定,以及用于治疗目的的TILs分离和扩增方法。重点介绍了正在进行的临床试验以及在不同癌症类型中取得的令人鼓舞的结果,包括黑色素瘤、卵巢癌和结直肠癌。本文还关注当前为改进基于TIL的疗法所做的努力,即鉴定在治疗癌症中最有效的特定TILs亚群,以及开发增强TILs在肿瘤微环境中功能性和持久性的方法。本文总结了TILs治疗的现状、正在进行的研究及其疗效的改进。

展开英文摘要原文

Tumor-infiltrating lymphocytes (TILs) are a subtype of immune cells that infiltrate and accumulate within tumors. Studies proved that TILs can be used as prognostic and predictive markers for cancer patients' responses to immunotherapy. This review explores the modern knowledge of TILs, the challenges and opportunities for utilizing TILs in cancer treatment, such as the rise of therapies under TIL circumstances, the identification of biomarkers for TIL activity, and methods used to isolate and expand TILs for therapeutic use.

Ongoing clinical trials and promising results in different cancer types are highlighted, including melanoma, ovarian, and colorectal cancer. This also focuses on ongoing efforts to improve TIL-based therapies by identifying the specific subsets of TILs that are most effective in treating cancer and developing methods to increase the functionality and persistence of TILs in the tumor microenvironment. The article recapitulates the present state TILs therapy, ongoing research, and improvements to its potency.

论文信息

作者
Aizaz M、Khan AS、Khan M、Musazade E、Yang G
第一作者单位
Shandong Provincial Key Laboratory of Animal Resistance Biology, College of Life Science, Shandong Normal University, Jinan, China. Electronic address: aizaz.sdnu@gmail.com.China
通讯作者单位
Shandong Provincial Key Laboratory of Animal Resistance Biology, College of Life Science, Shandong Normal University, Jinan, China. Electronic address: yanggw@sdnu.edu.cn.China
文献类型
综述
期刊
Critical reviews in oncology/hematology2024 Oct
原文标识
PubMed 39117163 · DOI 10.1016/j.critrevonc.2024.104471